Molbio Diagnostics, a leading point-of-care (POC) diagnostics company, has announced an exclusive collaboration with UE LifeSciences, a Philadelphia-based health technology innovator focused on early cancer detection. This strategic partnership aims to make early Breast Cancer detection accessible to millions of women across more than 50 developing countries.
As part of the collaboration, Molbio will introduce iBreastExam — a painless, radiation-free, and U.S. Food and Drug Administration-cleared screening device from UE LifeSciences — to regions including India, Africa, the Middle East, CIS countries, the Philippines, Indonesia, and Vietnam. The initiative aims to combat late detection — one of the primary contributors to preventable breast cancer deaths.
Leveraging its extensive global distribution network, Molbio will promote, market, sell, and distribute iBreastExam to public and private healthcare providers, expanding access to early screening in underserved regions.
The iBreastExam is a portable, battery-operated point-of-care device designed to detect breast lumps within minutes, without pain, radiation, or complex infrastructure. Using advanced sensor technology, it enhances and automates clinical breast examinations without requiring interpretation by the user. Secure cloud storage enables seamless follow-up and continuity of care.
“Our collaboration with Molbio Diagnostics is an important step towards improving access to early breast health screening, particularly in areas where access to screening remains a challenge,” said Mihir Shah, founder and CEO of UE LifeSciences. “Molbio’s experienced team and market reach can help amplify our mission to transform women’s health and save lives through accessible and innovative early detection.”
Breast cancer remains the most common cancer in women globally, contributing significantly to cancer-related mortality.
Molbio Diagnostics focuses on expanding access to rapid, accurate, and cost-effective point-of-care diagnostics for both infectious and non-communicable diseases, while UE LifeSciences is an award-winning women’s health company committed to making early detection of leading cancers in women equitable and accessible worldwide.